The United Kingdom and the United States have secured a significant trade agreement that will guarantee no tariffs on UK medicine exports entering the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to boost spending on medicines through the NHS. This pledge secures that import taxes on these crucial goods will be held at nothing for a period of the next three years.
This development is in response to recent statements to significantly raise duties on patented drug products, with potential rates discussed reaching 100%.
"This arrangement between the UK strengthens the international landscape for cutting-edge drugs and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Significance
Pharmaceuticals are one of the Britain's largest goods shipped to the United States, which is clearly the largest destination for leading British pharmaceutical firms.
Export figures show that in the one-year period prior to September, the UK shipped drugs valued at billions to the US. This value made up a significant portion of British export trade in that period.
"This guarantee protects employment, stimulates capital expenditure and sets the stage for the UK to become a global hub for medical research," the Business and Trade Secretary stated.
Specific UK Commitments
The agreement includes several notable commitments from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to increase total public funding on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage drug companies must pay back to the NHS to control costs will be capped at 15%. Last year, rebates exceeded 20%.
Recent Tensions
The pact comes amid a ongoing tension between the drug companies and the ministers over drug pricing and NHS adoption.
The disagreement were exacerbated by assertions that US consumers were paying a premium for the equivalent treatments than patients in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar expansions have been pledged toward projects in the United States.
One official acknowledged that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had shrunk as a share of its overall budget over the past decade.
